You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in exocrine and endocrine insufficiency. CP is a common disorder associated with significant morbidity and mortality with an incidence of 8.2 and a prevalence of 27.4 per 100 000 population. The etiolog ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A turn-key optogenetics and electrophysiology measurement system

    SBC: Pinnacle Technology, Inc.            Topic: NIA

    ABSTRACT Age-related sleep problems such as advanced sleep phase disorder (ASPD) are estimated to affect at least 1% of middle-aged adults and increase in prevalence with age. While the detrimental effects of sleep disruption with aging are well characterized, detailed insights into the molecular and physiological mechanisms underlying these sleep changes are greatly lacking. Optogenetics harnesse ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. PRECLINICAL TESTING OF HUMAN GHRELIN AND GROWTH HORMONE FOR SEPSIS IN THE ELDLY

    SBC: THERASOURCE, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The ultimate goal of our proposal is to develop a novel therapeutic approach that will save lives of aged septic patients. Sepsis is the most common cause of death in the non-cardiac intensive care units (ICU). It is particularly a serious problem in the geriatric population. The elderly (e 65 years of age) accounts for 12% of the US population but 65% of sepsi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV

    SBC: TECHNOVAX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that ov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A Therapeutic for Radiation Induced Lung Injury

    SBC: Angion Biomedica Corp.            Topic: NIAID

    DESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or partial-body irradiation. The risk of exposure to ionizingradiation due to terrorist activities could result in acute injury as well as long-term adverse health effects in thousands of people. The lung ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil

    SBC: ADJUVANCE TECHNOLOGIES INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Antitumor and anti-infectious disease vaccines require adjuvants in order to obtain optimal immunogenicity and therapeutic and protective efficacy. QS-21 is a natural saponin fraction that significantly out-performs other adjuvants in eliciting productive antibody and T-cell responses. It has remained the adjuvant of choice and has proven it's potency as i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION: There is a growing consensus that protection against HIV infection will require BOTH antiviral antibody responses as well as polyfunctional CD4+ and CD8+ T cells with potent lytic activity. To stimulate the breadth, potency, and rate of response required, Profectus Biosciences intends to utilize its platform technologies based on electroporation of DNA vaccines combined with genetic a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Spiral Countercurrent Chromatography for High-throughput Natural Product Purifica

    SBC: CC BIOTECH LLC            Topic: NCCIH

    DESCRIPTION (provided by applicant): Recent advances in countercurrent chromatography (CCC) have created novel spiral-design separation columns that hold a very high stationary phase of all the solvent systems, such that now all molecules of any size and water solubility can be successfully separated in high-speed countercurrent chromatography. With spiral CCC there is inherent versatility, more t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Real-time qPCR assay for detection of ALT associated telomeric C-circle DNA in bl

    SBC: Capital Biosciences, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The overall goal of the proposed project is to investigate the feasibility of employing real-time qPCR method for detection of telomeric C-circle DNA in peripheral blood of patients with cancers that utilize Alternative Lengthening of Telomeres (ALT) as their Telomere length Maintenance Mechanism (TMM). Telomeric C-Circle DNA has been demonstrated to be specif ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Biomarker Breast Pap Test

    SBC: SILBIOTECH, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase I research proposal is to investigate the feasibility of developing a novel Biomarker Breast PapTest for screening Nipple Aspirate Fluid (NAF) and detecting breast cancers at the tumor-in-formation stage before mammographically detectable tumors are developed. Although there is a slight decline in deaths from breast cancer in recent years, it conti ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government